BRD4 and cancer: We find that the cancer-related truncated variants comprising residues 1-645 and 1-591 of ASXL1 (ASXL1<sup>1-645</sup> and ASXL1<sup>1-591</sup>) retain BRD4 binding function, with ASXL1<sup>1-645</sup> showing an enhanced ability to recruit BRD4 to promoters of ASXL1 target genes.